From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast No 2: picking a fight with Tim Kempster

By Tom Winnifrith | Wednesday 11 June 2025


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I'm not really picking a fight with the short seller as he is basically a good chap but he has tweeted on Optibiotix (OPT) and Skinbiotherapeutics (SBTX) and he has, I think, got his facts wrong. For someone who may have an undeclared short position, that is perhaps unwise. I have swapped emails with at one CEO. If the other gets back to me I shall let you know but he is a bearded poltroon so many not.. I am also rowing with our in-house BB savant PL on NPVs ref Ariana (AAU). I cover Celadon (CEL) and revise my sordid price targets for Wishbone (WSBN) after news of a placing. I fear that the brothers in bromance, Richard Poulden and David Lenigas, are losing their ramping touch.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CLAI

CelAI madness begets madness

Monday »

ICON

Iconic Labs, the world has gone mad!

Time left: 17:23:13